

Application filed electronically through EFS-Web

FORM PTO-1380 (REV. 04/2006)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER 1830.1023
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (If known, see 37 CFR 1.5 unassigned 107580863
INTERNATIONAL APPLICATION NO. PCT/JP2004/017562	INTERNATIONAL FILING DATE November 26, 2004	PRIORITY DATE CLAIMED November 28, 2003
TITLE OF INVENTION NONREDUCING β-GLUCAN DERIVATIVE		
APPLICANT(S) FOR DO/EO/US Kazuhiro OBAE et al.		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<p>1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (22) indicated below.</p> <p>4. <input checked="" type="checkbox"/> The US has been elected (Article 31).</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input checked="" type="checkbox"/> has been communicated by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</p> <p>6. <input checked="" type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). a. <input checked="" type="checkbox"/> is attached hereto. b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).</p> <p>7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made.</p> <p>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p>10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p> <p>11. <input type="checkbox"/> For publication of assignee information under 37 CFR 1.215(b), list the assignee as ASAHI KASEI CHEMICALS CORPORATION of Tokyo, Japan. The Assignment papers will be filed later.</p> <p>Items 11 to 21 below concern document(s) or information included:</p> <p>12. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>13. <input checked="" type="checkbox"/> An assignment document and separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included for recording to ASAHI KASEI CHEMICALS CORPORATION of Tokyo, Japan.</p> <p>14. <input checked="" type="checkbox"/> A preliminary amendment.</p> <p>15. <input type="checkbox"/> An Application Data Sheet under 37 CFR 1.76.</p> <p>16. <input type="checkbox"/> A substitute specification.</p> <p>17. <input type="checkbox"/> A power of attorney and/or change of address letter.</p> <p>18. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.</p> <p>19. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).</p> <p>20. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).</p> <p>21. <input checked="" type="checkbox"/> Other items or information: Japanese language PCT-EASY transmittal for International Application PCT/JP2004/017562; Cover page of International Publication No. WO 2005/052008; & Form PCT/IB/304.</p>		

U.S. APPLICATION NO. (If known, use PCT/1.67) Unassigned	INTERNATIONAL APPLICATION NO. 107580863 PCT/JP2004/017562	ATTORNEY'S DOCKET NUMBER 1830.1023		
22. <input checked="" type="checkbox"/> The following fees are submitted:		APPLICANT USE ONLY		
<input checked="" type="checkbox"/> a) Basic National Fee..... \$300.00 <input checked="" type="checkbox"/> b) Examination Fee If the written opinion prepared by ISA/US or the international preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1) - (4) \$0 All other situations \$200.00				
23. <input checked="" type="checkbox"/> c) Search Fee (37 CFR 1.492(b)) If the written opinion of the ISA/US or the International preliminary examination report prepared by IPEA/US indicates all claims satisfy provisions of PCT Article 33(1) - (4)..... \$0 Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Search Authority ...\$100 International Search Report prepared by an ISA other than the US and provided to the Office or previously communicated to the US by the IB \$400 All other situations \$500		\$300.00		
TOTAL OF ABOVE CALCULATIONS =		\$ \$1000.00		
<input type="checkbox"/> Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each addition 50 sheets of paper or fraction thereof.				
Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof	Rate	
39 - 100 =	/50=		X 250.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(h)).			\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$
Total claims	25- 20 =	5	X \$50.00	\$250.00
Independent claims	2- 3 =		X \$200.00	\$
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$360.00	\$
TOTAL OF ABOVE CALCULATIONS =				\$1250.00
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.			\$	
SUBTOTAL =				\$1250.00
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(i)).			\$	
TOTAL NATIONAL FEE =				\$1250.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property			+ \$40.00	
TOTAL FEES ENCLOSED =				\$1290.00
Amount to be refunded:				\$
Amount to be charged:				\$

10/580863

'APQ Rec'd PCT/PTO 26 MAY 2006

- A check in the amount of \$1290.00 to cover the above fees is enclosed.
- Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.
- The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-3935. A duplicate copy of this sheet is enclosed.
- Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Staas & Halsey LLP
1201 New York Avenue, N.W., 7th Floor
Washington, DC 20005

M. J. Henry
SIGNATURE

Mark J. Henry

NAME May 26 2006

Date

36,162
REGISTRATION NUMBER

©2006 Staas & Halsey LLP